MAximising Therapeutic Utility in Rheumatoid Arthritis
Toggle navigation
Home
Our Research
TranSMART
About Us
About Us
Academic and Industry Partners
News and publications
Patient/Public Involvment
What is MATURA?
EPIC-RA – Patient Survey
Get Involved MPAG
Highlights and News
Jargon buster
Synovial biopsy: patient interview
Contact Us
Highlights and News
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition - Frontiers
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition
Frontiers
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue
Nature
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts - The Lancet
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts
The Lancet
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis
Frontiers
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK - The BMJ
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK
The BMJ
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Nature
Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases - Wiley Online Library
Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases
Wiley Online Library
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - The Lancet
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
The Lancet
Sankey diagram depicting treatment sequencing for bDMARDs in patients... - ResearchGate
Sankey diagram depicting treatment sequencing for bDMARDs in patients...
ResearchGate
Clinical Applications of Synovial Biopsy - Frontiers
Clinical Applications of Synovial Biopsy
Frontiers
TABLE 1 | Rheumatoid synovial tissue studies of biologic and targeted... - ResearchGate
TABLE 1 | Rheumatoid synovial tissue studies of biologic and targeted...
ResearchGate
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
Nature
Rheumatoid arthritis - The Lancet
Rheumatoid arthritis
The Lancet
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis - Frontiers
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis
Frontiers
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy
Frontiers
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes - Frontiers
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes
Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients - Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients
Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs - Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs
Frontiers
Related
What is MATURA?
EPIC-RA – Patient Survey
Get Involved MPAG
Highlights and News
The MATURA consortium
includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis
Home
| Copyright © Experimental Medicine & Rheumatology Department, Queen Mary University London, 2015 - 2025 |
Sitemap